← Research & Industry News
External source
Ultragenyx to lay off 20% of employees, scrap a Wilson disease gene therapy
After a whirlwind third quarter that saw two FDA approvals but a major setback in Angelman syndrome, Ultragenyx is laying off staff for the second time this year. The California biopharma
- Published by
- Endpoints News
- Evidence type
- Regulatory
After a whirlwind third quarter that saw two FDA approvals but a major setback in Angelman syndrome, Ultragenyx is laying off staff for the second time this year. The California biopharma
This item was selected automatically by our daily literature and news monitor because it matches the topics we follow. Read the full story at Endpoints News.
Let's engineer the next delivery breakthrough together
We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through scale-up.
ResearchersRequest a technical consultationTalk formulation, characterisation or assay design with one of our scientists.Industry partnersExplore co-developmentFeasibility studies, co-development programmes and licensing.InvestorsExplore the market opportunitySourced market sizes, pipeline, investment and deal data for genetic medicine delivery.